DRI Healthcare Trust (TSE:DHT.UN) Sets New 52-Week High – Should You Buy?

DRI Healthcare Trust (TSE:DHT.UN) shares hit a new 52-week high during mid-day trading on Monday. The stock traded as high as C$19.75 and last traded at C$19.67, with a volume of 24,523 shares changing hands. The stock had previously closed at C$19.23.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on DHT.UN shares. National Bank Financial lifted their price objective on DRI Healthcare Trust from C$23.50 to C$25.50 and gave the company an “outperform” rating in a report on Tuesday, September 22nd. Stifel Nicolaus lifted their price target on shares of DRI Healthcare Trust from C$25.00 to C$26.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating and four have given a Buy rating to the stock. According to MarketBeat.com, DRI Healthcare Trust presently has a consensus rating of “Buy” and an average target price of C$25.60.

DRI Healthcare Trust Trading Up 2.1%

The firm has a market capitalization of C$1.08 billion, a price-to-earnings ratio of 18.19 and a beta of 0.09. The company’s 50 day moving average is C$17.99 and its 200-day moving average is C$17.34.

DRI Healthcare Trust Company Profile

DRI Healthcare is a pioneer in global pharmaceutical royalty monetization. Since our founding in 1989, we have deployed more than $3 billion, acquiring more than 75 royalties on 50-plus drugs, including Eylea, Keytruda, Lumvoa, Orserdu, Remicade, Spinraza, Stelara, Vonjo and Zytiga. DRI Healthcare’s units are listed and trade on the TSX in Canadian dollars under the symbol ‘DHT.UN’ and in U.S. dollars under the symbol ‘DHT.U’. To learn more, visit drihealthcare.com or follow us on LinkedIn.